23 results Stibbe advises leading plasma protein biotherapeutics company Stibbe advised a plasma protein biotherapeutics company on Belgium's implementation of a new Act on public procurement law that obliges Belgian hospitals to conduct a public procurement process for public contracts for the supply of medicinal products. Stibbe advises biotech company Stibbe advised a leading biotechnology company on the legal aspects of clinical trials development for biotech medicinal products. Stibbe advises major pharmaceutical company Stibbe assisted a global innovative pharmaceutical company in a complex co-marketing and co-promotion agreement and advised it on the impact of an innovative product’s registration at the European Medicines Agency. Stibbe advises Cellerix Stibbe assisted Cellerix with its merger with Euronext-Brussels-listed Tigenix. Temporary authorisations for certain biocidal products to tackle the Corona crisis: unusual times call for unusual (temporary) measures The outbreak of the Covid-19 crisis has been officially acknowledged as a pandemic and public health crisis. In response, the Belgian authorities have decided to proceed with the grant of temporary authorisations for certain biocidal product types. Pagination Previous page Page 1 Current page 2
Stibbe advises leading plasma protein biotherapeutics company Stibbe advised a plasma protein biotherapeutics company on Belgium's implementation of a new Act on public procurement law that obliges Belgian hospitals to conduct a public procurement process for public contracts for the supply of medicinal products.
Stibbe advises biotech company Stibbe advised a leading biotechnology company on the legal aspects of clinical trials development for biotech medicinal products.
Stibbe advises major pharmaceutical company Stibbe assisted a global innovative pharmaceutical company in a complex co-marketing and co-promotion agreement and advised it on the impact of an innovative product’s registration at the European Medicines Agency.
Stibbe advises Cellerix Stibbe assisted Cellerix with its merger with Euronext-Brussels-listed Tigenix.
Temporary authorisations for certain biocidal products to tackle the Corona crisis: unusual times call for unusual (temporary) measures The outbreak of the Covid-19 crisis has been officially acknowledged as a pandemic and public health crisis. In response, the Belgian authorities have decided to proceed with the grant of temporary authorisations for certain biocidal product types.